Mesothelin CAR Therapy With PD-L1 Blockade for Tumor Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer therapies targeting mesothelin expression, such as mesothelin CAR-T therapy and PD-L1 inhibitors, have limitations in efficacy and require improved strategies to enhance tumor inhibition.
Innovation Solution
A combination therapy using chimeric antigen receptor (CAR)-expressing cells that target mesothelin and PD-L1 inhibitors, administered sequentially or concurrently, to enhance tumor inhibition in subjects with mesothelin-associated diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If mesothelin CAR-T therapy is used alone, then tumor targeting is achieved, but therapeutic efficacy is insufficient
Solution Approach 1:
The patent combines mesothelin CAR-T therapy with PD-L1 inhibitors into a single integrated treatment protocol. The CAR-T cells express both mesothelin-specific chimeric antigen receptors and are co-administered with PD-L1 blocking antibodies, creating a synergistic dual-mechanism therapy that overcomes tumor resistance while maintaining manageable complexity through coordinated administration schedules
2Reliability
If PD-L1 inhibitors are used alone, then immune checkpoint blockade is achieved, but tumor inhibition is insufficient
Solution Approach 1:
The patent employs PD-L1 inhibitors as a preliminary action before or concurrent with CAR-T cell therapy. By blocking the PD-L1 checkpoint pathway in advance, the tumor microenvironment is primed to be more responsive to subsequent CAR-T cell infiltration and activation, enhancing overall tumor inhibition while structuring the treatment sequence to manage complexity
3Reliability
If combination therapy is used, then therapeutic efficacy is enhanced, but treatment complexity increases
Solution Approach 1:
The patent implements periodic administration schedules for the combination therapy, with PD-L1 inhibitors given at specific intervals (e.g., every 3 weeks) and CAR-T cells administered at defined timepoints relative to inhibitor dosing. This periodic structure maintains therapeutic efficacy through sustained immune activation while reducing complexity by establishing a predictable, repeatable treatment cycle
Data Source
Figure 1A
Figure 1B
Figure 2
AI summary
Provided are compositions for use in methods for treating diseases associated with expression of mesothelin comprising administering a cell that expresses a chimeric antigen receptor (CAR) specific to mesothelin in combination with a PD-L1 inhibitor.